InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
-2.7%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Alles Mark J, Director. Officer active across 4 companies, notably Turning Point Therapeutics, Inc.. Aggregated, 21 filings have been logged. Breakdown: 3 buys · 0 sell. Total volume traded: €589k. Activity tracked since 21 June 2021. The latest transaction was filed on 23 May 2023 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations21 total
2,666 sharesCommon StockSEC:0001209191-23-049977:0
4,190 shares0Common StockSEC:0001209191-23-031964:0
3,625 shares@ US$86.75100.0% of flowCommon StockSEC:0001567619-22-019081:0
Ideal exit: 28 Jul 2023 (T+270)
2,000 shares@ US$76.0035.3% of flowCommon StockSEC:0001209191-22-046273:0
4,980 shares0Common StockSEC:0001567619-22-011784:0
2,300 shares0Common StockSEC:0001567619-22-000661
2,300 shares0Common StockSEC:0001567619-22-000661:0
2,000 shares@ US$81.3432.3% of flowCommon StockSEC:0001209191-21-042325
Ideal exit: 18 Mar 2022 (T+270)
2,000 shares@ US$81.3450.0% of flowCommon StockSEC:0001209191-21-042325:0
Ideal exit: 18 Mar 2022 (T+270)
25,840 sharesCommon StockSEC:0001209191-16-098803:0
11,889 sharesCommon StockSEC:0001209191-16-098803:1
2,634 sharesCommon StockSEC:0001209191-16-094811:0
4,528 sharesCommon StockSEC:0001209191-16-094811:1
2,438 sharesCommon StockSEC:0001209191-16-094811:2
1,266 sharesCommon StockSEC:0001209191-16-094811:3
2,500 sharesCommon StockSEC:0001209191-16-094811:4
1,926 sharesCommon StockSEC:0001209191-16-094811:5
2,292 sharesCommon StockSEC:0001209191-16-094811:6
1,128 sharesCommon StockSEC:0001209191-16-094811:7
1,720 sharesCommon StockSEC:0001209191-16-094811:8
1,506 sharesCommon StockSEC:0001209191-16-094811:9
21 of 21 declarations
About Alles Mark J
Mark J. Alles is a Director at Turning Point Therapeutics, Inc. and BioMarin Pharmaceutical Inc. He plays a key role in the governance and strategy of these companies. Turning Point Therapeutics is a biopharmaceutical company focused on developing treatments for cancer. Mark brings valuable expertise in the field, contributing to the direction and growth of the companies.
